Tag: Eric H. Rubin
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given ... Read More